All News
GRAPPA: the 2015 guidelines and the initial draft (still in revision) of the purposed 2021 guidelines. Dr. Kavanaugh We've been busy getting approved treatments options for our PsA patients over the past few years!
@RWCSmtg #RNL2022 @RheumNow https://t.co/CJGrNbg6MA
Dr. Rachel Tate uptoTate ( View Tweet)
Welcome to an in person and online hybrid mtg. The future of delivering #CME any way you order it. #RNL2023 @RheumNow https://t.co/PI1XKtqGIu
Janet Pope Janetbirdope ( View Tweet)
#RNL2022 How do you use guidelines?
@RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
ANA
▶️Short lived plasma cell DNA.
▶️Long lived plasma cell ANA RNP.
Peter Lipsky @rhumnow #Rnl2022 https://t.co/U7YkCBEEFJ
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
#ClinicalPearl Urinary biomarkers for #SLE #nephritis are still mostly too ‘dilute’ for prime time. Albumin/creative spot urine and #microalbuminuria are still v Impt @RheumNow #RNL2022 https://t.co/uEWs0saSX3
Janet Pope Janetbirdope ( View Tweet)
Lupus heterogeneity:
Anti Smith Anti RNP more common in certain ethnicity , more interferon production and aggressive disease!!!
Peter Lipsky @rhumnow #Rnl2022 https://t.co/xGhafD4l8k
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
HEp-2 cell and ACR classification criteria:
Peter Lipsky @rhumnow #Rnl2022 https://t.co/6o6epkjqB4
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Avoid screening with ANA, PLEASE!!
Normal postive ANA
Peter Lipsky @rhumnow #Rnl2022 https://t.co/GEKmhQfpfm
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Remarkable heterogeneity in results of #ANA testing using different assays #PeterLipsky on “Almighty ANA” at #RNL2022 @RheumNow https://t.co/A0y3ugBBrz
Elena MyasoedovaMD MyasoedovaElena ( View Tweet)
ANA levels fluctuate & depend on the https://t.co/rjZhNvSzE1 should we use it as an entry criterion to diagnose lupus ? #RNL2022
Links:
madan madanpadmajan1 ( View Tweet)
ANA in otherwise healthy:
Anti-DFS70 antibodies (Dense Fine Speckled, 70kDa molecular weight) are a sub-group of anti-nuclear antibodies.
Peter Lipsky @rhumnow #Rnl2022 https://t.co/QH4qsdzZmu
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Q and A
Positive ANA post COVID infection and vaccination?
⬇️
1- Repeat test ( transient elevation).
2-Monitor clinical symptoms.
PS, COVID infection ▶️lupus anti coagulant and catastrophic APS like syndrome.
@RheumNow #Rnl2022
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
ANA variability among different platforms and essays.
Validated quantification test are needed!!
Peter Lipsky @rhumnow #rnl2022 https://t.co/pyJhBkJE8P
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Top Influencers of #RNL2022: @doctorRBC @hausmannMD @RheumNow @uptoTate @NoufAhmedAlham2 @Janetbirdope More 📊 https://t.co/5tIzMLfqrh
Symplur Hashtags healthhashtags ( View Tweet)
Dr. Kavanaugh reviews the process of guidelines/recommendations. It's a lot of work! #RNL2022 @RWCSmtg @RheumNow https://t.co/z48mVKweVq
Dr. Rachel Tate uptoTate ( View Tweet)
POD 3 on Psoriatic Arthritis Advances will begin at 2pm ET and Dr. Artie Kavanaugh will lead the first presentation of the pod titled PsA Guidelines: The Good, Bad & Ugly. #RNL2022 https://t.co/cx3XBSWbNr
Dr. John Cush RheumNow ( View Tweet)
Anifrolumab high incidence of herpes zoster #RNL2022
madan madanpadmajan1 ( View Tweet)
Dr. Narain: SLE flare risk w/ HCQ tapering/reducing dose vs maintaining.
Retinopathy risk:
💎doubles every 5 yrs of use
💎^ w/ ^ dosing per ABW
💎^ w/ IBW in dose-response manner
💎independent risk factors: cumulative HCQ use, duration of use, CKD, Asian decent #RNL2022 @RheumNow https://t.co/lgMNEmQEhl
Dr. Rachel Tate uptoTate ( View Tweet)
Interesting potential upcoming SLE treatments
Data from China
Improvement of SRI-4 response rate compared to placebo
@RheumNow #RNL2022 https://t.co/VE5Tza7xt8
Robert B Chao, MD doctorRBC ( View Tweet)
Anifrolumab and lupus.
Don not forget Herpes zoster vaccination!!
Sonail Narain @RheumNow #Rnl2022 https://t.co/hNWaSHH27d
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)